...
首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKCδ-driven migration
【24h】

VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKCδ-driven migration

机译:肾细胞癌中VHL的丧失导致含有CUB结构域的蛋白1上调以刺激PKCδ驱动的迁移

获取原文
获取原文并翻译 | 示例
           

摘要

A common genetic mutation found in clear cell renal cell carcinoma (CC-RCC) is the loss of the von Hippel-Lindau (VHL) gene, which results in stabilization of hypoxia-inducible factors (HIFs), and contributes to cancer progression and metastasis. CUB-domain-containing protein 1 (CDCP1) was shown to promote metastasis in scirrhous and lung adenocarcinomas as well as in prostate cancer. In this study, we established a molecular mechanism linking VHL loss to induction of the CDCP1 gene through the HIF-1/2 pathway in renal cancer. Also, we report that Fyn, which forms a complex with CDCP1 and mediates its signaling to PKCS, is a HIF-1 target gene. Mechanistically, we found that CDCP1 specifically regulates phosphorylation of PKCS, but not of focal adhesion kinase or Crk-associated substrate. Signal transduc-tion from CDCP1 to PKCS leads to its activation, increasing migration of CC-RCC. Furthermore, patient survival can be stratified by CDCP1 expression at the cell surface of the tumor. Taken together, our data indicates that CDCP1 protein might serve as a therapeutic target for CC-RCC.
机译:在透明细胞肾细胞癌(CC-RCC)中发现的常见基因突变是von Hippel-Lindau(VHL)基因的丢失,这导致了缺氧诱导因子(HIFs)的稳定,并有助于癌症的发展和转移。含CUB结构域的蛋白1(CDCP1)已显示出可促进肝硬化和肺腺癌以及前列腺癌的转移。在这项研究中,我们建立了一种通过HIF-1 / 2途径在肾癌中将VHL丢失与CDCP1基因诱导联系起来的分子机制。同样,我们报告Fyn,它与CDCP1形成复合物并介导其向PKCS的信号传导,是HIF-1靶基因。从机理上讲,我们发现CDCP1特异性调节PKCS的磷酸化,但不调控粘着斑激酶或Crk相关底物的磷酸化。从CDCP1到PKCS的信号转导导致其激活,增加了CC-RCC的迁移。此外,可以通过肿瘤细胞表面的CDCP1表达来对患者的生存进行分层。综上所述,我们的数据表明CDCP1蛋白可能充当CC-RCC的治疗靶标。

著录项

  • 来源
  • 作者单位

    Department of Radiation Oncology, Center for Clinical Sciences Research, Stanford University School of Medicihe, Stanford, CA 94305;

    Department of Radiation Oncology, Center for Clinical Sciences Research, Stanford University School of Medicihe, Stanford, CA 94305;

    Department of Radiation Oncology, Center for Clinical Sciences Research, Stanford University School of Medicihe, Stanford, CA 94305;

    Department of Radiation Oncology, Center for Clinical Sciences Research, Stanford University School of Medicihe, Stanford, CA 94305;

    lnstitute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, Stanford, CA 94305;

    lnstitute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, Stanford, CA 94305;

    Department of Radiation Oncology, Center for Clinical Sciences Research, Stanford University School of Medicihe, Stanford, CA 94305;

    Department of Biochemistry, Case Western Reserve University, Cleveland, OH 44106;

    Department of Radiation Oncology, Center for Clinical Sciences Research, Stanford University School of Medicihe, Stanford, CA 94305;

    Department of Radiation Oncology, Center for Clinical Sciences Research, Stanford University School of Medicihe, Stanford, CA 94305;

    Department of Radiation Oncology, Center for Clinical Sciences Research, Stanford University School of Medicihe, Stanford, CA 94305;

    Department of Radiation Oncology, Center for Clinical Sciences Research, Stanford University School of Medicihe, Stanford, CA 94305;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号